Diisobutyl phthalate


Curated chemical-gene interactions from CTD
Entrez gene IDGene symbolInteraction typeReference
10682 EBP Decreases expression PMID:33983380
111785 HSD3B Decreases expression PMID:22112501
13121 CYP51 Decreases expression PMID:33983380
15494 HSD3B3 Decreases expression PMID:33983380
1583 CYP11A1 Decreases expression PMID:16458459; PMID:21633115; PMID:22112501
1584 CYP11B1 Decreases expression PMID:22112501; PMID:33983380
1585 CYP11B2 Decreases expression PMID:33983380
1586 CYP17A1 Decreases expression PMID:22112501; PMID:28655647; PMID:33983380
1717 DHCR7 Decreases expression PMID:33983380
190 NR0B1 Decreases expression PMID:33983380
2099 ESR1 Increases activity PMID:15840436; PMID:27633901; PMID:28571686
2100 ESR2 Increases activity PMID:27633901; PMID:28571686
217 ALDH2 Decreases expression PMID:33983380
2224 FDPS Decreases expression PMID:33983380
269 AMHR2 Increases expression PMID:22112501
3156 HMGCR Decreases expression PMID:28655647; PMID:33983380
3157 HMGCS1 Decreases expression PMID:28655647; PMID:33983380
3293 HSD17B3 Increases expression PMID:28655647
3623 INHA Decreases expression PMID:33983380
3638 INSIG1 Decreases expression PMID:33983380
3640 INSL3 Decreases expression PMID:22112501; PMID:33983380
3949 LDLR Decreases expression PMID:33983380
4597 MVD Decreases expression PMID:33983380
50814 NSDHL Decreases expression PMID:33983380
5468 PPARG Increases activity PMID:24155963; PMID:27633901; PMID:26172262
5468 PPARG Increases expression PMID:29061543
6258 RXRG Decreases expression PMID:22112501
6662 SOX9 Increases expression PMID:22112501
6770 STAR Decreases expression PMID:16458459; PMID:21633115; PMID:22112501; PMID:28655647; PMID:33983380
7068 THRB Decreases activity PMID:27633901
7108 TM7SF2 Decreases expression PMID:33983380
8856 NR1I2 Increases activity PMID:21227907
949 SCARB1 Decreases expression PMID:22112501; PMID:28655647; PMID:33983380
9970 NR1I3 Increases activity PMID:21227907

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.